A few key rea­sons why Bio­gen has now be­come a buzzed about takeover tar­get

Strug­gling with rev­enue and keep­ing in­vestors’ in­ter­est in its pipeline as its CEO heads for the ex­its, Bio­gen has drawn some in­ter­est from two big play­ers about a pos­si­ble takeover. The Wall Street Jour­nal re­port­ed Tues­day af­ter­noon that Al­ler­gan and Mer­ck have both made over­tures to Bio­gen to sound out their in­ter­est in a deal.

Bio­gen’s shares $BI­IB raced up 9%, adding bil­lions in mar­ket cap as the in­vest­ment com­mu­ni­ty looked to jump in­to a pos­si­ble deal in the mak­ing. But by ear­ly Tues­day evening CN­BC was fol­low­ing up with a re­port that Al­ler­gan, which may have had a hard time mak­ing a buy­out work un­der cur­rent tax rules, was un­like­ly to fol­low up.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA